Is the stem cell trade back on ahead of next week’s biotech conference? The traders talk how to play stem cells without investing in risky, small biotech companies.
Even if 2008 brings a stem cell-friendly candidate to the White House, the technology is still years away from being perfected, Pete Najarian said. Geron (GERN) is the only real “pure play” on stem cells, and it has plummeted from its high of $75 in 2000. But biotech names like Celgene (CELG), Amgen (AMGN) and AstraZeneca (AZN) are ways to get ahead of stem cells without all the risk of a Geron, he said.
Even if 2008 brings a stem cell-friendly candidate to the White House, the technology is still years away from being perfected, Pete Najarian said. Geron (GERN) is the only real “pure play” on stem cells, and it has plummeted from its high of $75 in 2000. But biotech names like Celgene (CELG), Amgen (AMGN) and AstraZeneca (AZN) are ways to get ahead of stem cells without all the risk of a Geron, he said.
______________________________________________________
Got something to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to fastmoney@cnbc.com.
Trader disclosure: On Sept. 20, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (ATVI), (EMC); Najarian Owns (AAPL), (VMW), (CREE); Finerman's Firm Owns (BEAS), (LTD), (BWS), (NMX), (NYX), (COP), (KALU); Finerman's Firm Owns S&P 500 Puts; Finerman's Firm Owns Russell 2000 Puts; Finerman's Firm And Finerman Own (HD)